FOR INVESTORS

Disease outmatched by the science of degradation

FOR INVESTORS

Disease outmatched by the science of degradation

FOR INVESTORS

Disease outmatched by the science of degradation

Nurix is a biopharmaceutical company accelerating development of medicines based on targeted protein degradation, the next frontier to outmatch cancer and autoimmune diseases.

More About Nurix

View All

Minimum 15 minutes delayed. Source: LSEG

SEC Filings

April 08, 2026

Report of unscheduled material events or corporate event

8-K
View HTML
0001549595-26-000024.pdf
0001549595-26-000024.rtf
0001549595-26-000024.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

April 08, 2026

Quarterly report which provides a continuing view of a company's financial position

10-Q
View HTML
0001549595-26-000025.pdf
0001549595-26-000025.rtf
0001549595-26-000025.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

April 02, 2026

Filed by "insiders" prior intended sale of restricted stock.

144
View HTML
0001950047-26-003216.pdf
0001950047-26-003216.rtf
0001950047-26-003216.xls

View All

Disease outmatched by the science of degradation

Disease outmatched by the science of degradation

Disease outmatched by the science of degradation

News

Events

2026 Annual Meeting of Stockholders

25th Annual Needham Virtual Healthcare Conference

44th Annual J.P. Morgan Healthcare Conference

SEC Filings

Inside The Science

Advancing Our Pipeline

Learn About Us

Work at Nurix

For Investors

For Patients